{"id":"neostigmine-glycopyrolate","safety":{"commonSideEffects":[{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Muscle fasciculations"},{"rate":null,"effect":"Increased salivation (if glycopyrolate inadequate)"},{"rate":null,"effect":"Bronchospasm"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Neostigmine is a cholinesterase inhibitor that prevents the breakdown of acetylcholine, thereby enhancing cholinergic neurotransmission. Glycopyrolate is an anticholinergic agent added to this combination to block unwanted muscarinic effects (such as excessive salivation, bronchospasm, and bradycardia) that would otherwise result from neostigmine monotherapy. Together, they provide enhanced nicotinic effects while minimizing parasympathomimetic adverse effects.","oneSentence":"Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrolate blocks muscarinic receptors to counteract parasympathomimetic side effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:56:55.399Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reversal of neuromuscular blockade following anesthesia"},{"name":"Myasthenia gravis (neostigmine component)"}]},"trialDetails":[{"nctId":"NCT03513406","phase":"PHASE3","title":"Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-03-15","conditions":"Burns","enrollment":7},{"nctId":"NCT03574337","phase":"PHASE4","title":"Residual Neuromuscular Blockade in Cardiac Surgery Patients","status":"WITHDRAWN","sponsor":"Henry Ford Health System","startDate":"2018-08-01","conditions":"Residual Neuromuscular Blockade","enrollment":""},{"nctId":"NCT04105764","phase":"PHASE4","title":"Deep NMB in Ambulatory Gynecological Laparoscopy","status":"COMPLETED","sponsor":"Wahba bakhet","startDate":"2016-12-01","conditions":"Muscle Relaxation","enrollment":80},{"nctId":"NCT03881423","phase":"PHASE4","title":"Deep vs Moderate Neuromuscular Blockade in Day Case Laparoscopic Cholecystectomy.","status":"COMPLETED","sponsor":"Wahba bakhet","startDate":"2017-04-01","conditions":"Muscle Relaxation","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"neostigmine/glycopyrolate","genericName":"neostigmine/glycopyrolate","companyName":"Henry Ford Health System","companyId":"henry-ford-health-system","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrolate blocks muscarinic receptors to counteract parasympathomimetic side effects. Used for Reversal of neuromuscular blockade following anesthesia, Myasthenia gravis (neostigmine component).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}